Oncology

These findings support the potential role of ctDNA in prognostic assessment and early intervention.

Patients with psychiatric disorders had higher CRC risk but no increase in CRC-specific mortality.

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast cancer care and payer friction.

This meta-analysis, which found no statistically significant OS differences by sex, age, or race with ICIs, highlights the need for more diverse, representative NSCLC trials.

Young adults with metastatic CRC (mCRC) and low socioeconomic status (SES) face higher 3-year mortality, whereas race was not independently linked with survival.

Patients with proinflammatory, pro-oxidative diets may face accelerated biological aging and increased skin cancer risk.

Based on these findings, the investigators encourage further research into this promising combination.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

Danielle Roman, PharmD, BCOP, explains why a collaborative, team-based approach is essential to solving resource challenges in community cancer care.

Eric H. Yang, MD, emphasizes the need for collaboration and interventions to protect patients’ hearts during breast cancer treatment.

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed key aspects of the KEYNOTE-B96 trial of paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Only about 2% of cases of rhabdomyosarcoma primarily arise from the chest wall, and such cases require careful planning.

Global ovarian and uterine cancer cases due to high BMI have risen sharply over the past 30 years, especially in low- to middle-income sociodemoraphic regions.

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.